Novo Nordisk to discontinue Levemir insulin in U.S. market

 Novo Nordisk (NOVOb.CO) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.